$488.58
2.67% yesterday
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US5588681057
Symbol
MDGL

Madrigal Pharmaceuticals, Inc. Stock price

$488.58
+46.27 10.46% 1M
+193.45 65.55% 6M
+180.01 58.34% YTD
+150.36 44.46% 1Y
+423.92 655.61% 3Y
+364.69 294.37% 5Y
+465.83 2,047.93% 10Y
+170.43 53.57% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
+12.71 2.67%
ISIN
US5588681057
Symbol
MDGL
Industry

New AI Insights on Madrigal Pharmaceuticals, Inc. Insights AI Insights on Madrigal Pharmaceuticals, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$11.1b
Enterprise Value
$10.4b
Net debt
positive
Cash
$797.0m
Shares outstanding
22.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
21.5 | 12.4
EV/Sales
20.2 | 11.7
EV/FCF
negative
P/B
15.9
Financial Health
Equity Ratio
72.4%
Return on Equity
-61.8%
ROCE
-37.8%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$515.6m | $893.0m
EBITDA
$-308.4m | $-264.1m
EBIT
$-309.8m | $-276.0m
Net Income
$-281.9m | $-212.6m
Free Cash Flow
$-308.4m
Growth (TTM | estimate)
Revenue
3,421.5% | 395.8%
EBITDA
41.8% | 46.8%
EBIT
41.6% | 44.6%
Net Income
44.8% | 54.4%
Free Cash Flow
32.3%
Margin (TTM | estimate)
Gross
96.3%
EBITDA
-59.8% | -29.6%
EBIT
-60.1%
Net
-54.7% | -23.8%
Free Cash Flow
-59.8%
More
EPS
$-12.7
FCF per Share
$-13.9
Short interest
19.2%
Employees
528
Rev per Employee
$340.0k
Show more

Is Madrigal Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

20x Buy
87%
2x Hold
9%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy
87%
Hold
9%
Sell
4%

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
516 516
3,422% 3,422%
100%
- Direct Costs 19 19
2,897% 2,897%
4%
496 496
3,446% 3,446%
96%
- Selling and Administrative Expenses 614 614
136% 136%
119%
- Research and Development Expense 193 193
32% 32%
37%
-308 -308
42% 42%
-60%
- Depreciation and Amortization 1.42 1.42
100% 100%
0%
EBIT (Operating Income) EBIT -310 -310
42% 42%
-60%
Net Profit -282 -282
45% 45%
-55%

In millions USD.

Don't miss a Thing! We will send you all news about Madrigal Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Madrigal Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 16 hours ago
CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Induc...
Neutral
Seeking Alpha
3 days ago
Madrigal Pharmaceuticals, Inc. ( MDGL ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Tina Ventura - Chief Investor Relations Officer William Sibold - CEO, President & Director David Soergel - Executive VP & Chief Medical Officer Mardi Dier - Executive VP & CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer ...
Neutral
GlobeNewsWire
3 days ago
Third -quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025 , more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, re...
More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office United States
CEO William Sibold
Employees 528
Founded 2011
Website www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today